New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3

Stock Information for Ebix Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Ebix Inc.

Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis
Aclaris Therapeutics to Participate in Two June Healthcare Conferences
Aclaris Therapeutics to Participate in the HC Wainwright "HCW@Home" Series
Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer
Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling Advancement of its Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody
Aclaris Therapeutics to Participate in Two March Healthcare Conferences
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.